# Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

> **NCT05780905** · PHASE4 · RECRUITING · sponsor: **University of Washington** · enrollment: 50 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Stroke (CVA) or Transient Ischemic Attack

## Interventions

- **DRUG:** Semaglutide Auto-Injector
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05780905
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780905, "Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05780905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*